Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Medtronic
Argus Health
Deloitte
Teva
Cantor Fitzgerald
Novartis
Healthtrust
Covington
Express Scripts

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,277,780

« Back to Dashboard

Which drugs does patent 8,277,780 protect, and when does it expire?

Patent 8,277,780 protects TOPICORT and is included in one NDA.

This patent has four patent family members in four countries.
Summary for Patent: 8,277,780
Title:Stable liquid desoximethasone compositions with reduced oxidized impurity
Abstract: The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C.sub.2-C.sub.4 alcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt % isopropyl myristate; c) about 20 wt % to about 70 wt % C.sub.2-C.sub.4 alcohol; and d) a stabilizing agent selected from the group consisting of an oleaginous vehicle and a propellant, wherein the stabilizing agent is in an amount sufficient to reduce the formation of less than about 1 wt % 17-carboxy-9.alpha.-fluoro-11.beta.-hydroxy-16a-methyl-androsta-1,4-diene- -3-one under an accelerated storage condition.
Inventor(s): Rao; Srinivasa (Valley Stream, NY), Dixit; Suresh (Fort Worth, TX), Yacobi; Avraham (Englewood, NJ), Bailey; Arthur (Bethel, CT)
Assignee: Taro Pharmaceutical North America, Inc. (Grand Cayman, KY)
Application Number:11/921,106
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Delivery; Use; Process;

Drugs Protected by US Patent 8,277,780

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Taro TOPICORT desoximetasone SPRAY;TOPICAL 204141-001 Apr 11, 2013 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,277,780

PCT Information
PCT FiledMay 26, 2006PCT Application Number:PCT/US2006/020561
PCT Publication Date:December 07, 2006PCT Publication Number: WO2006/130510

Non-Orange Book US Patents Family Members for Patent 8,277,780

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,715,624 Stable liquid desoximethasone compositions with reduced oxidized impurity ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,277,780

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel 187666 ➤ Try a Free Trial
European Patent Office 1888026 ➤ Try a Free Trial
Canada 2609579 ➤ Try a Free Trial
World Intellectual Property Organization (WIPO) 2006130510 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Boehringer Ingelheim
QuintilesIMS
US Army
Queensland Health
Covington
UBS
Argus Health
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot